{"id":130228,"date":"2021-08-23T11:00:00","date_gmt":"2021-08-23T11:00:00","guid":{"rendered":"https:\/\/icrowdnewswire.com\/?p=2902534"},"modified":"2021-08-23T11:00:00","modified_gmt":"2021-08-23T11:00:00","slug":"neuexcell-therapeutics-names-russ-addis-as-vice-president-research","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/","title":{"rendered":"NeuExcell Therapeutics names Russ Addis as Vice President, Research"},"content":{"rendered":"

\"\"<\/p>\n

August 23, 2021. State College, Pennsylvania\u00a0 \u2013 NeuExcell Therapeutics Inc. (www.neuexcell.com<\/a>) today announced the appointment of Russ Addis, Ph.D. to the new position of Vice President, Research, effective immediately.<\/p>\n

Dr. Addis will report directly to Dr. Ronald HW Lorijn, Chief Executive Officer, and will oversee the Company\u2019s gene therapy programs. Dr. Addis leads a growing organization and will build on the earlier activities and current expansion of the lab and programs.<\/p>\n

Dr. Addis joins NeuExcell after 8+ years of industry leadership experience at various startup biotech companies and several years of research experience at the University of Pennsylvania\u2019s Institute for Regenerative Medicine. Prior to NeuExcell, Dr. Addis established and led the research program at Aro Biotherapeutics, developing targeted genetic medicines for rare disease. Having expertise in multiple therapeutic areas including gene therapy, neurodegeneration, rare disease, aging and oncology puts Addis in an excellent position to lead NeuExcell\u2019s research efforts.<\/p>\n

Dr. Addis received his undergraduate degree from the University of Pennsylvania (with a double major in Biochemistry & Biology), and his Ph.D. (in Human Genetics & Molecular Biology) from the Johns Hopkins University School of Medicine.<\/p>\n

\u201cWe are very excited to have Russ step into this new role at NeuExcell,\u201d said Dr. Lorijn. \u201cThis addition to our team reflects NeuExcell\u2019s increasing focus on our internal innovation to ensure long-term growth for the company and for the benefit of all those suffering from devastating neurodegenerative diseases.\u201d<\/p>\n

\u201cRuss has the unique combination of in-depth knowledge and experiences in neuroscience, gene therapy and regenerative medicine,\u201d said Professor Gong Chen, NeuExcell\u2019s co-founder and Chief Scientific Advisor. \u201cWe are confident that Russ will lead us on an accelerating pace to advance our research programs toward the clinic.\u201d<\/p>\n

About NeuExcell Therapeutics<\/h3>\n

NeuExcell is a privately held early-stage gene technology company headquartered in Pennsylvania, USA. Its mission is to improve the lives of patients suffering from neuro-degenerative diseases and CNS injuries. Based upon the scientific work of Prof. Gong Chen, the Company has developed a potentially disruptive neural repair technology through astrocyte-to-neuron conversion in-vivo by introducing neural transcription factors through adeno-associated virus (AAV)-based gene therapy. NeuExcell\u2019s pipeline covers major neurodegenerative diseases as Stroke, Huntington\u2019s, Amyotrophic Lateral Sclerosis, Alzheimer\u2019s Disease, Parkinson\u2019s Disease, Traumatic Brain Injury, Spinal Cord Injuries, and Cancer.<\/p>\n

NeuExcell Therapeutics <\/u>Media Contact<\/u>:<\/h3>\n

Xi Qin, MBA<\/p>\n

Chief Financial Officer<\/p>\n

NeuExcell Therapeutics, Inc.<\/p>\n

xiqin@neuexcell.com<\/a><\/p>\n

814-826-5966<\/p>\n

www.neuexcell.com<\/p>\n

Tags: leadership<\/a>, Gene Therapy<\/a>, NeuExcell<\/a>, Neuroregeneration<\/a>, CNS<\/a>, Transdifferentiation<\/a> <\/p>\n

See Campaign: <\/strong>https:\/\/neuexcell.com\/<\/a>
Tags:<\/b>
ReleaseLive<\/a>, Menafn<\/a>, IPS<\/a>, Reportedtimes<\/a>, Google News<\/a>, Financial Content<\/a>, PR-Wirein<\/a>, Extended Distribution<\/a>, iCN Internal Distribution<\/a>, English<\/a><\/p>\n<\/div>\n

The post NeuExcell Therapeutics names Russ Addis as Vice President, Research<\/a> appeared first on Financial Market Brief<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

August 23, 2021. State College, Pennsylvania  – NeuExcell Therapeutics Inc. (www.neuexcell.com) today announced the appointment of Russ Addis, Ph.D. to the new position of Vice President, Research, effective immediately. Dr. Addis will report directly to Dr. Ronald HW Lorijn, Chief Executive Officer, and will oversee the Company’s gene therapy programs. Dr. Addis leads a growing […]<\/p>\n

The post NeuExcell Therapeutics names Russ Addis as Vice President, Research<\/a> appeared first on Financial Market Brief<\/a>.<\/p>\n

Continue Reading →<\/span><\/a><\/p>\n","protected":false},"author":291,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-130228","post","type-post","status-publish","format-standard","hentry","category-press-release"],"yoast_head":"\nNeuExcell Therapeutics names Russ Addis as Vice President, Research - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuExcell Therapeutics names Russ Addis as Vice President, Research - Business\" \/>\n<meta property=\"og:description\" content=\"August 23, 2021. State College, Pennsylvania  – NeuExcell Therapeutics Inc. (www.neuexcell.com) today announced the appointment of Russ Addis, Ph.D. to the new position of Vice President, Research, effective immediately. Dr. Addis will report directly to Dr. Ronald HW Lorijn, Chief Executive Officer, and will oversee the Company’s gene therapy programs. Dr. Addis leads a growing […] The post NeuExcell Therapeutics names Russ Addis as Vice President, Research appeared first on Financial Market Brief. Continue Reading →\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-23T11:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg\" \/>\n<meta name=\"author\" content=\"iCrowdNewswire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"iCrowdNewswire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/\",\"name\":\"NeuExcell Therapeutics names Russ Addis as Vice President, Research - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg\",\"datePublished\":\"2021-08-23T11:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage\",\"url\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg\",\"contentUrl\":\"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuExcell Therapeutics names Russ Addis as Vice President, Research\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee\",\"name\":\"iCrowdNewswire\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g\",\"caption\":\"iCrowdNewswire\"},\"sameAs\":[\"https:\/\/heymuse.com\/ips\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuExcell Therapeutics names Russ Addis as Vice President, Research - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/","og_locale":"en_US","og_type":"article","og_title":"NeuExcell Therapeutics names Russ Addis as Vice President, Research - Business","og_description":"August 23, 2021. State College, Pennsylvania  – NeuExcell Therapeutics Inc. (www.neuexcell.com) today announced the appointment of Russ Addis, Ph.D. to the new position of Vice President, Research, effective immediately. Dr. Addis will report directly to Dr. Ronald HW Lorijn, Chief Executive Officer, and will oversee the Company’s gene therapy programs. Dr. Addis leads a growing […] The post NeuExcell Therapeutics names Russ Addis as Vice President, Research appeared first on Financial Market Brief. Continue Reading →","og_url":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/","og_site_name":"Business","article_published_time":"2021-08-23T11:00:00+00:00","og_image":[{"url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg","type":"","width":"","height":""}],"author":"iCrowdNewswire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"iCrowdNewswire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/","url":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/","name":"NeuExcell Therapeutics names Russ Addis as Vice President, Research - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"primaryImageOfPage":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage"},"image":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage"},"thumbnailUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg","datePublished":"2021-08-23T11:00:00+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#primaryimage","url":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg","contentUrl":"https:\/\/icrowdnewswire.com\/wp-content\/uploads\/2021\/08\/NeuExcell.jpg"},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2021\/08\/23\/neuexcell-therapeutics-names-russ-addis-as-vice-president-research\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"NeuExcell Therapeutics names Russ Addis as Vice President, Research"}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/bde271d5882ffdcb71d1a2a961b51fee","name":"iCrowdNewswire","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/aa079ec4d87ad6117c9db7a1a2cde1607ee2f869010252c2d0af346f0047b325?s=96&d=mm&r=g","caption":"iCrowdNewswire"},"sameAs":["https:\/\/heymuse.com\/ips"],"url":"https:\/\/ipsnews.net\/business\/author\/icrowdnewswire\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130228","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/291"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=130228"}],"version-history":[{"count":2,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130228\/revisions"}],"predecessor-version":[{"id":130244,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/130228\/revisions\/130244"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=130228"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=130228"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=130228"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}